Female infertility is typically defined as the inability to achieve pregnancy after one year of attempting conception. A wide range of factors may cause female infertility, such as age, obesity, type 2 diabetes, and endometriosis. As such, there are numerous avenues to help these patients successfully conceive, including pharmacologic agents such as clomiphene citrate and follicle-stimulating hormone (e.g., Merck KGaA's Gonal F), as well as assisted reproductive technologies including in vitro fertilization. Thus, patient-specific considerations are often needed to determine the optimal plan for initiation of treatment. Pipeline agents (e.g., ObsEva’s nolasiban) are seeking to capitalize on unmet need for improving pregnancy rates, particularly for patients undergoing assisted reproductive technology-based procedures.
- How large is the prevalent population of females patients suffering from infertility?
- What are the most common causes of female infertility? Is this expected to change in the next 10 years?
- What are current treatment options for female infertility? How do reproductive endocrinologists approach different underlying causes of female infertility?
- What unmet needs remain for the treatment of different drivers of infertility?
- What are the most promising pipeline agents? How do experts believe these will fit into future treatment paradigms?
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
United States and EU5
- Six country-specific interviews with thought-leading reproductive endocrinologists
- Supported by survey data collected for this study
Total, diagnosed, and drug-treated prevalent cases of female infertility by country, total prevalent cases by etiology, number of procedures due to female infertility
Drug-level sales and patient share of key female infertility therapies in 2027
Phase III/PR: 1 drugs. Phase II: 2 drugs. Coverage of select preclinical and Phase I products.
- Female Infertility - Landscape And Forecast - Disease Landscape And Forecast
Author(s): Michael Breen, PhD; Ema Rodrigues, DSc, MPH
Michael is a business insights analyst on the Infectious, Niche, and Rare Diseases team. He has authored reports on cystic fibrosis, nonalcoholic steatohepatitis, vaccines, and respiratory syncytial virus, and will author a report on cytomegalovirus. He also provides coverage for Decision Resources’ Company & Drug Insights covering anti-infectives, vaccines, and transplant therapy areas.
Michael received his Bachelor’s degree from Hunter College with a dual major in biology and biochemistry. He received his Ph.D. in biochemistry from Boston University School of Medicine. His postdoctoral research was carried out at Brigham and Women’s Hospital/Harvard Medical School, with a focus on identifying novel pathways regulating thermogenesis in search of a therapeutic for obesity and diabetes.
Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables.
She completed her master’s and doctoral degree (MPH, D.Sc.) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.